Copyright: ©Author(s) 2026.
World J Dermatol. Sep 16, 2026; 12(1): 121729
Published online Sep 16, 2026. doi: 10.5314/wjd.121729
Published online Sep 16, 2026. doi: 10.5314/wjd.121729
Table 1 Laboratory results at admission
| Parameter | Value | Reference range | Interpretation |
| Liver function | |||
| Total bilirubin (mg/dL) | 10.5 | 0.2-1.2 | ↑ markedly elevated |
| Direct bilirubin (mg/dL) | 7.2 | 0-0.3 | ↑↑ predominantly direct |
| Indirect bilirubin (mg/dL) | 3.3 | 0.2-0.9 | ↑ elevated |
| ALT (U/L) | 68 | 7-56 | ↑ mildly elevated |
| AST (U/L) | 95 | 10-40 | ↑ elevated |
| ALP (U/L) | 210 | 44-147 | ↑ elevated |
| GGT (U/L) | 320 | 8-61 | ↑↑ markedly elevated |
| Albumin (g/dL) | 2.2 | 3.5-5.0 | ↓ low - hepatic synthetic failure |
| INR | 1.9 | 0.8-1.1 | ↑ coagulopathy |
| PT (seconds) | 22 | 11-13.5 | ↑ prolonged |
| Renal function & electrolytes | |||
| Creatinine (mg/dL) | 1.3 | 0.7-1.3 | Upper normal |
| BUN (mg/dL) | 28 | 7-20 | ↑ mildly elevated |
| Sodium (mEq/L) | 132 | 136-145 | ↓ hyponatremia |
| Potassium (mEq/L) | 4.1 | 3.5-5.1 | Normal |
| Complete blood count | |||
| Hemoglobin (g/dL) | 10.2 | 13.5-17.5 | ↓ anemia |
| Platelets (× 103/µL) | 98 | 150-400 | ↓ thrombocytopenia |
| MCV (fL) | 105 | 80-100 | ↑ macrocytosis |
| Coagulation & inflammatory markers | |||
| aPTT (seconds) | 42 | 25-35 | ↑ prolonged |
| Fibrinogen (mg/dL) | 180 | 200-400 | ↓ low |
| CRP (mg/L) | 48 | < 5 | ↑↑ significantly elevated |
| Ammonia (µmol/L) | 72 | 9-33 | ↑ elevated |
| HBsAg/anti-HCV | Negative | Negative | — |
Table 2 Summary of previously published cases of yellow urticaria
| Ref. | Year | Age/sex | Underlying condition | Peak bilirubin (mg/dL) | Urticaria trigger | Treatment |
| Clarke[4] | 1969 | Adult/male | Hepatic cirrhosis | Elevated (NR) | Idiopathic | Antihistamines |
| Nava Cruz et al[2] | 2017 | 57 years/female | Biliary pancreatitis | 8.4 | Idiopathic | Antihistamines |
| Combalia et al[1] | 2017 | 63 years/male | Cirrhosis | 9.3 | Drug | Antihistamines |
| Combalia et al[1] | 2017 | 38 years/female | AIH/PBC overlap | 7.8 | Idiopathic | Antihistamines |
| Çakıcı et al[3] | 2021 | Adult/NR | Viral hepatitis B | 5.9 | Idiopathic | Antihistamines |
| Mendes et al[10] | 2018 | Adult/NR | ARV-induced liver injury | 4.5 | Drug (ARV) | Cessation + antihistamines |
| Hardy et al[9] | 2022 | 67 years/male | End-stage liver disease | 12.1 | FFP transfusion | Antihistamines |
| Kalsi et al[6] | 2024 | Adult/NR | Acalabrutinib hepatotoxicity | 6.8 | Drug | Cessation + steroids |
| Toujani et al[8] | 2023 | 33 years/female | AIH + PBC overlap | 6.2 | Idiopathic | Antihistamines |
| Gao et al[7] | 2025 | Adult/NR | Uncommon aetiology (NR) | NR | Idiopathic | Antihistamines |
| Present case | 2025 | 70 years/male | Decompensated alcoholic cirrhosis (CPC 11) | 10.5 (direct 7.2) | IV albumin (anaphylactoid) | IV hydrocortisone + chlorpheniramine + emollients |
- Citation: Ghostine N, Khalil LM, Beydoun K, Berjawi A. Yellow urticaria in a patient with decompensated alcoholic cirrhosis triggered by intravenous albumin infusion: A case report. World J Dermatol 2026; 12(1): 121729
- URL: https://www.wjgnet.com/2218-6190/full/v12/i1/121729.htm
- DOI: https://dx.doi.org/10.5314/wjd.121729